Cover ImageSALE
市場調查報告書

肝性腦病變(HE)治療藥的全球市場:2018年∼2022年

Global Hepatic Encephalopathy (HE) Therapeutics Market 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 603605
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
肝性腦病變(HE)治療藥的全球市場:2018年∼2022年 Global Hepatic Encephalopathy (HE) Therapeutics Market 2018-2022
出版日期: 2018年02月06日 內容資訊: 英文 102 Pages
簡介

關於肝性腦病變(HE)

HE,是由於肝臟損傷引起的潛在致命的腦功能障礙,因此導致血液毒素無法除去。

Technavio的分析師預測,從2018年到2022年之間全球肝性腦病變(HE)治療藥市場將以5.35%的年複合成長率成長。

本報告提供全球肝性腦病變(HE)治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 簡介

  • 市場概要

第5章 市場情形

  • 市場生命週期
  • 市場特性
  • 市場區隔分析

第6章 市場規模

  • 市場定義
  • 市場規模
  • 市場規模及預測

第7章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭的威脅
  • 市場情形

第8章 開發平台分析

第9章 市場區隔:各產品

  • 概要
  • 比較:各產品
  • NAD
  • 抗生素
  • 其他
  • 市場機會:各產品

第10章 市場區隔:各疾病重症度

  • 概要
  • CHE
  • OHE

第11章 客戶形勢

第12章 地區形勢

  • 地理市場區隔
  • 地區比較
  • 南北美洲
  • 歐洲、中東、非洲地區
  • 亞太地區
  • 主要的已開發國家
  • 市場機會

第13章 決策架構

第14章 成長要素與課題

  • 市場成長要素
  • 市場課題

第15章 市場趨勢

  • 技術的進步
  • 新治療目標出現

第16章 業者情勢

  • 概要
  • 創造性破壞

第17章 供應商分析

  • 交易廠商
  • 供應商的分類
  • 供應商的市場定位
  • Asuka製藥
  • COSMO PHARMACEUTICALS
  • Mallinckrodt
  • Valeant

第18章 附錄

  • 簡稱清單
目錄
Product Code: IRTNTR20766

About Hepatic Encephalopathy (HE) Therapeutics

HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.

Technavio's analysts forecast the global hepatic encephalopathy (HE) therapeutics market to grow at a CAGR of 5.35% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global hepatic encephalopathy (HE) therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Hepatic Encephalopathy (HE) Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • ASKA Pharmaceutical
  • COSMO PHARMACEUTICALS
  • Mallinckrodt
  • Valeant

Market driver

  • Availability of patient-focused programs to assist disease management
  • For a full, detailed list, view our report

Market challenge

  • Late and inaccurate diagnosis
  • For a full, detailed list, view our report

Market trend

  • Technological advances
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: PIPELINE ANALYSIS

PART 09: MARKET SEGMENTATION BY PRODUCT

  • Overview
  • Comparison by product
  • NADs
  • Antibiotics
  • Others
  • Market opportunity by product

PART 10: MARKET SEGMENTATION BY DISEASE SEVERITY

  • Overview
  • CHE
  • OHE

PART 11: CUSTOMER LANDSCAPE

PART 12: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas
  • EMEA
  • APAC
  • Key leading countries
  • Market opportunity

PART 13: DECISION FRAMEWORK

PART 14: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 15: MARKET TRENDS

  • Technological advances
  • Emergence of novel treatment targets

PART 16: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 17: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ASKA Pharmaceutical
  • COSMO PHARMACEUTICALS
  • Mallinckrodt
  • Valeant

PART 18: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Interorgan ammonia metabolism in healthy liver
  • Exhibit 02: WHC classification of HE
  • Exhibit 03: Recommended treatment pathway for HE
  • Exhibit 04: Parent market
  • Exhibit 05: Global CNS disorders drugs market: Segments
  • Exhibit 06: Market characteristics
  • Exhibit 07: Global HE therapeutics market: Segments
  • Exhibit 08: Market definition: Inclusions and exclusions checklist
  • Exhibit 09: Market size 2017
  • Exhibit 10: Validation techniques employed for market sizing 2017
  • Exhibit 11: Global HE therapeutics market 2017-2022 ($ millions)
  • Exhibit 12: Global HE therapeutics market: Year-over-year growth 2018-2022 (%)
  • Exhibit 13: Five forces analysis 2017
  • Exhibit 14: Five forces analysis 2022
  • Exhibit 15: Bargaining power of buyers
  • Exhibit 16: Bargaining power of suppliers
  • Exhibit 17: Threat of new entrants
  • Exhibit 18: Threat of substitutes
  • Exhibit 19: Threat of rivalry
  • Exhibit 20: Market condition: Five forces 2017
  • Exhibit 21: Pipeline landscape by development phase
  • Exhibit 22: Key clinical trials
  • Exhibit 23: Global HE therapeutics market: Segmentation by product 2017-2022 (%)
  • Exhibit 24: Comparison by product
  • Exhibit 25: Global NAD HE therapeutics market 2017-2022 ($ millions)
  • Exhibit 26: Global NAD HE therapeutics market: Year-over-year growth 2018-2022 (%)
  • Exhibit 27: Global antibiotic HE therapeutics market 2017-2022 ($ millions)
  • Exhibit 28: Global antibiotic HE therapeutics market: Year-over-year growth 2018-2022 (%)
  • Exhibit 29: Global other HE therapeutics market 2017-2022 ($ millions)
  • Exhibit 30: Global other HE therapeutics market: Year-over-year growth 2018-2022 (%)
  • Exhibit 31: Market opportunity by product
  • Exhibit 32: Customer landscape
  • Exhibit 33: Global HE therapeutics market: Segmentation by geography 2017-2022 (%)
  • Exhibit 34: Regional comparison
  • Exhibit 35: HE therapeutics market in Americas 2017-2022 ($ millions)
  • Exhibit 36: HE therapeutics market in Americas: Year-over-year growth 2018-2022 (%)
  • Exhibit 37: HE therapeutics market in EMEA 2017-2022 ($ millions)
  • Exhibit 38: HE therapeutics market in EMEA: Year-over-year growth 2018-2022 (%)
  • Exhibit 39: HE therapeutics market in APAC 2017-2022 ($ millions)
  • Exhibit 40: HE therapeutics market in APAC: Year-over-year growth 2018-2022 (%)
  • Exhibit 41: Key leading countries
  • Exhibit 42: Market opportunity
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: ASKA Pharmaceutical: Overview
  • Exhibit 49: ASKA Pharmaceutical: Business segments
  • Exhibit 50: ASKA Pharmaceutical: Organizational developments
  • Exhibit 51: ASKA Pharmaceutical: Segment focus
  • Exhibit 52: ASKA Pharmaceutical: Key offerings
  • Exhibit 53: ASKA Pharmaceutical: Key customers
  • Exhibit 54: COSMO PHARMACEUTICALS: Overview
  • Exhibit 55: COSMO PHARMACEUTICALS: Business segments
  • Exhibit 56: COSMO PHARMACEUTICALS: Organizational developments
  • Exhibit 57: COSMO PHARMACEUTICALS: Segment focus
  • Exhibit 58: COSMO PHARMACEUTICALS: Key offerings
  • Exhibit 59: COSMO PHARMACEUTICALS: Key customers
  • Exhibit 60: Mallinckrodt: Overview
  • Exhibit 61: Mallinckrodt: Business segments
  • Exhibit 62: Mallinckrodt: Organizational developments
  • Exhibit 63: Mallinckrodt: Geographic focus
  • Exhibit 64: Mallinckrodt: Segment focus
  • Exhibit 65: Mallinckrodt: Key offerings
  • Exhibit 66: Mallinckrodt: Key customers
  • Exhibit 67: Valeant: Overview
  • Exhibit 68: Valeant: Business segments
  • Exhibit 69: Valeant: Organizational developments
  • Exhibit 70: Valeant: Geographic focus
  • Exhibit 71: Valeant: Segment focus
  • Exhibit 72: Valeant: Key offerings
  • Exhibit 73: Valeant: Key customers
Back to Top